Malignant Hyperthermia Update. Anesthesiol Clin 2020 Mar;38(1):165-181
Date
02/06/2020Pubmed ID
32008650DOI
10.1016/j.anclin.2019.10.010Scopus ID
2-s2.0-85078799124 (requires institutional sign-in at Scopus site) 29 CitationsAbstract
Malignant hyperthermia (MH) is a rare but potentially lethal skeletal muscle disorder affecting calcium release channels. It is inherited in a mendelian autosomal dominant pattern with variable penetration. The initial clinical manifestations are of a hypermetabolic state with increased CO2 production, respiratory acidosis, increased temperature, and increased oxygen demands. If diagnosed late, MH progresses to multi-organ system failure and death. Current data suggest that mortality has improved to less than 5%. The gold standard for ruling out MH is the contracture test. Genetic testing is also available. MH-susceptible individuals should be clearly identified for safe administration of future anesthetics.
Author List
Ellinas H, Albrecht MAAuthor
Meredith A. Albrecht MD, PhD Associate Professor in the Anesthesiology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnesthesiaHumans
Malignant Hyperthermia
